Genetically engineered mice to specifically express the Ezh2Y641F point mutation in B cells develop GCB-like lymphomas in cooperation with BCL2 or BCL6 overexpression (Béguelin et al., 2013; Béguelin et al., 2016). This evidence concerns the gene BCL2 and lymphoma.